[Cellular cardiomyoplasty: state of the art, evaluation, and future possibilities].
Cellular cardiomyoplasty, or the transplantation of myogenic cells into the myocardial tissues, could emerge as a therapeutic alternative in patients with cardiac failure. It depends on several procedures: implantation of cell types, syngenic embryonic cardiomycocytes, allogenic and autogenic cardiac muscle cells. These cells carne into contact with host cardiomyocytes and could contract in a synchronous fashion. Experimental data suggests that this technique could improve global left ventricular function in the post-infarction period or in dilated cardiomyopathy even though the precise mechanism of this improvement is not fully understood. Many difficulties remain, the cell types have an oncogenic potential; syngenic foetal cells are weakly immunogenic but their use is limited by ethical and problems of supply. Therefore, auto-transplantation either of cardiomycocytes obtained by endomyocardial biopsy or of adult skeletal muscle, could be a potential clinical option.
Hagège
A
A
Laboratoire d'imagerie médicale, Faculté de médecine Necker-Enfants malades, Paris.
Scorsin
M
M
Samuel
J L
JL
Rappaport
L
L
Ménasché
P
P
D000328:Adult; D018421:Cardiomyoplasty / Q000379:methods / Q000639:trends*; D004992:Ethics, Medical; D016332:Fetal Tissue Transplantation; D005544:Forecasting; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy; D009206:Myocardium / Q000166:cytology*; D019739:Skeletal Muscle Ventricle; D014182:Transplantation, Autologous; D016277:Ventricular Function, Left
Cardiomyoplastie cellulaire. Etat des lieux, évaluation et avenir.